SCHEMBL21681983

SCHEMBL21681983

O=C(Nc1nc2ccc(C(=O)Nc3c(Cl)cccc3Cl)cc2s1)c1ccc2ncccc2c1

nearest known ligand 0.62

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LCK P06239 19/20 0.62
FYN P06241 1/20 0.59
SRC P12931 1/20 0.59
HSD17B1 P14061 1/20 0.57
HSD17B2 P37059 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21772286 0.88 LCK (0.64) LCKFYNSRCHSD17B1HSD17B2
SCHEMBL6057930 0.82 LCK (0.80) LCKFYNSRC
SCHEMBL6058259 0.79 LCK (0.82) LCKFYNSRC
SCHEMBL6058264 0.79 LCK (0.89) LCKFYNSRC
SCHEMBL6058279 0.79 LCK (0.81) LCKFYNSRC
SCHEMBL21709936 0.78 NPC1 (0.67) LCKFYNSRC
SCHEMBL6058162 0.78 LCK (0.75) LCKFYNSRC
SCHEMBL6057906 0.77 LCK (1.00) LCKFYNSRC
SCHEMBL6058252 0.77 LCK (0.70) LCKFYNSRC
SCHEMBL6058083 0.76 LCK (1.00) LCKFYNSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200071316-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF Kineta Immuno-Oncology LLC 2020-03-05 US claimed
WO-2020033782-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-1\" PATHWAY AND METHODS OF USE THEREOF Kineta, Inc. (US) 2020-02-13 WO claimed
US-20200071316-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF Kineta Immuno-Oncology LLC 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071316-A1 ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF RARB, RARG, RARA LCK 4191/4885FYN 4777/4885SRC 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.